|
|
Volumn 307, Issue 24, 2012, Pages 2576-2577
|
|
FDA and pharma seek better ways to assess drug safety, efficacy in clinical trials
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AZATHIOPRINE;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
CLINICAL PROTOCOL;
CLINICAL TRIAL (TOPIC);
DRUG CONTROL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG SAFETY;
EXPERIMENTAL DESIGN;
FOOD AND DRUG ADMINISTRATION;
GRAFT REJECTION;
HIGH RISK PATIENT;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
INFECTION PREVENTION;
INFECTION RISK;
INTENTION TO TREAT ANALYSIS;
PATIENT ATTITUDE;
PRESCRIPTION;
PRIORITY JOURNAL;
RISK ASSESSMENT;
RISK FACTOR;
SHORT SURVEY;
SYSTEMATIC ERROR;
|
|
EID: 84862841145
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2012.6684 Document Type: Short Survey |
|
Times cited : (5)
|
|
References (0)
|
